This trial is testing a drug called CM-AT to see if it is safe and effective in treating children with autism who have all levels of fecal chymotrypsin.
1 Primary · 1 Secondary · Reporting Duration: Change from Baseline to each post-baseline visit, through study completion Week 72.
405 Total Participants · 1 Treatment Group
Primary Treatment: CM-AT · No Placebo Group · Phase 3
Age < 18 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Detroit Clinical Research Center, P.C.||100.0%|